Evaluation of Thyroid Function in Patients With Chronic Kidney Disease
Study Details
Study Description
Brief Summary
A higher prevalence of thyroid disease has been associated with chronic kidney disease (CKD), and subclinical hypothyroidism seems to be the most common dysfunction. The aim is to evaluate thyroid function and autoimmunity in patients with CKD stages 3, 4 and 5. Cross-sectional study to be carried out on patients with stages 3 and 4 in a Nephrology outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb) levels.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
Cross-sectional study to be carried out on patients with stages 3, 4 and 5 in a Nephrology outpatient clinic. Thyroid function is evaluated by measuring thyroid stimulating hormone (TSH), free thyroxine, free triiodothyronine and antithyroperoxidase antibodies (TPOAb) levels. Free Thyroxine (FT4) will be measured by liquid chromatography tandem mass spectrometry and electrochemiluminescence immunoassay in order to compare methods in this population.
The glomerular filtration rate was estimated (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration formula (CKD-EPI), and the CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO).
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Chonic kidney disease stages 3, 4 and 5 Patients with stage chronic kidney disease stages 3, 4 and 5. CKD stages were defined according to the Kidney Disease Improving Global Outcomes directives (KDIGO): a) stage 3A: eGFR 45 and 59 ml/min/1.73m2; b) stage 3B: eGFR between 30 and 44 ml/min/1.73m2; c) stage 4: eGFR between 15 and 29 ml/min/1.73 m2 |
Diagnostic Test: Thyroid function
laboratorial thyroid tests
|
Outcome Measures
Primary Outcome Measures
- Free thyroxine (FT4) levels in chronic kidney disease [through study completion, an average of 3 years]
Free thyroxine levels through two different methods
- TSH levels in chronic kidney disease [through study completion, an average of 3 years]
TSH levels
Secondary Outcome Measures
- Frequency of thyroid antibodies in chronic kidney disease [through study completion, an average of 3 years]
antithyroperoxidase and antitireoglobulin antibodies
- Free triiodothyronine (FT3) levels in chronic kidney disease [through study completion, an average of 3 years]
T3 levels
Eligibility Criteria
Criteria
Inclusion Criteria:Patients over 18 years old with CKD stages 3 and 4 were included in the study.
-
Exclusion Criteria: 1) acute systemic inflammatory disease; 2) pituitary disease in the past or present; 3) regular treatment with amiodarone, lithium, interferon, immunosuppressive drugs and glucocorticoids; 4) previously diagnosed hypothyroidism and undergoing levothyroxine replacement.
-
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Ana Beatriz Winter Tavares | Petrópolis | RJ | Brazil | 25665-442 |
Sponsors and Collaborators
- Rio de Janeiro State University
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
- Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol. 2012 Jan;23(1):22-6. doi: 10.1681/ASN.2010070766. Epub 2011 Oct 21. Review.
- Meuwese CL, Gussekloo J, de Craen AJ, Dekker FW, den Elzen WP. Thyroid status and renal function in older persons in the general population. J Clin Endocrinol Metab. 2014 Aug;99(8):2689-96. doi: 10.1210/jc.2013-3778. Epub 2014 Apr 15.
- Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016 Oct;23(5):407-15. doi: 10.1097/MED.0000000000000275. Review.
- 3.138.270